Effects of nicotine on cytochrome P450 2A6 and 2E1 activities.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Smoking slows the metabolism of nicotine and accelerates the metabolism of chlorzoxazone, which are probe reactions for cytochrome P450 2A6 (CYP2A6) and CYP2E1 activities, respectively.

The researchers aimed to determine the role of nicotine in these metabolic effects of cigarette smoking.

Who Took Part

The age groups tagged for this paper are young adults, adults, middle-aged adults and older adults, both men and women.

The subjects abstained from smoking during the study arms.

How the Study Was Run

The design is described as randomized, single-blind, placebo-controlled and crossover.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Only one side, usually the participants, was kept unaware of whether Therapeutic nicotine (patch, non-peptide) was given.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

The study had a single-blind, randomized, crossover two-arm design.

Oral chlorzoxazone was given on day 7 and deuterium-labelled nicotine-d(2) and cotinine-d(4) infusion on day 8.

What Was Measured

PubMed files the paper under topics including Aryl Hydrocarbon Hydroxylases, Chlorzoxazone, Cotinine, Cytochrome P-450 CYP2E1, Cytochrome P-450 Enzyme System, Drug Interactions and Metabolic Clearance Rate.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (British journal of clinical pharmacology), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.